DOCSLIB.ORG

Genes Investigated

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

BabyNEXTTM EXTENDED Investigated genes and associated diseases Gene Disease OMIM OMIM Condition RUSP gene Disease ABCC8 Familial hyperinsulinism 600509 256450 Metabolic disorder - ABCC8-related Inborn error of amino acid metabolism ABCD1 Adrenoleukodystrophy 300371 300100 Miscellaneous RUSP multisystem (C) * diseases ABCD4 Methylmalonic aciduria and 603214 614857 Metabolic disorder - homocystinuria, cblJ type Inborn error of amino acid metabolism ACAD8 Isobutyryl-CoA 604773 611283 Metabolic Disorder - RUSP dehydrogenase deficiency Inborn error of (S) ** organic acid metabolism ACAD9 acyl-CoA dehydrogenase-9 611103 611126 Metabolic Disorder - (ACAD9) deficiency Inborn error of fatty acid metabolism ACADM Acyl-CoA dehydrogenase, 607008 201450 Metabolic Disorder - RUSP medium chain, deficiency of Inborn error of fatty (C) acid metabolism ACADS Acyl-CoA dehydrogenase, 606885 201470 Metabolic Disorder - RUSP short-chain, deficiency of Inborn error of fatty (S) acid metabolism ACADSB 2-methylbutyrylglycinuria 600301 610006 Metabolic Disorder - RUSP Inborn error of (S) organic acid metabolism ACADVL very long-chain acyl-CoA 609575 201475 Metabolic Disorder - RUSP dehydrogenase deficiency Inborn error of fatty (C) acid metabolism ACAT1 Alpha-methylacetoacetic 607809 203750 Metabolic Disorder - RUSP aciduria Inborn error of (C) organic acid metabolism ACSF3 Combined malonic and 614245 614265 Metabolic Disorder - methylmalonic aciduria Inborn error of organic acid metabolism 1 ADA Severe combined 608958 102700 Primary RUSP immunodeficiency due to Immunological (S) ADA deficiency deficiency ADK Hypermethioninemia due to 102750 614300 Metabolic Disorder - RUSP adenosine kinase deficiency Inborn error of (S) amino acid metabolism AGL Glycogen storage disease, 610860 232400 Other Disorders type III AGXT Primary hyperoxaluria, type 604285 259900 1 AHCY Hypermethioninemia with 180960 613752 Metabolic Disorder - RUSP deficiency of S- Inborn error of (S) adenosylhomocysteine amino acid hydrolase metabolism AK2 Reticular dysgenesis 103020 267500 Primary Immunological deficiency AKR1D1 Bile acid synthesis defect, 604741 235555 congenital, 3 ALDH4A1 Hyperprolinemia, type II 606811 239510 Metabolic disorder - Inborn error of amino acid metabolism ALDH7A1 Epilepsy, pyridoxine- 107323 266100 Neurotransmitter dependent Disorders ALDOB Fructose intolerance, 612724 229600 Metabolic Disorder - hereditary Inborn error of organic acid metabolism ALPL Hypophosphatasia 171760 241500 ANK1 Spherocytosis, type 2 612641 182900 AQP2 Diabetes insipidus, 107777 125800 nephrogenic 2 ARG1 Argininemia 608313 207800 Metabolic Disorder - RUSP Inborn error of (S) amino acid metabolism ARSA Metachromatic 607574 250100 Lysosomal Storage leukodystrophy Disorders (LSD) ARSB Mucopolysaccharidosis type 611542 253200 Lysosomal Storage VI (Maroteaux-Lamy) Disorders (LSD) ASL Argininosuccinic aciduria 608310 207900 Metabolic Disorder - RUSP Inborn error of (C) amino acid metabolism ASS1 Citrullinemia Type 1 603470 215700 Metabolic Disorder - RUSP Inborn error of (C) amino acid metabolism AUH 3-methylglutaconic aciduria, 600529 250950 Metabolic Disorder - RUSP type I Inborn error of (S) organic acid metabolism AVPR2 Nephrogenic syndrome of 300538 300539 inappropriate antidiuresis / Nephrogenic diabetes insipidus AVPR2-related BCKDHA Maple syrup urine disease, 608348 248600 Metabolic Disorder - RUSP type Ia Inborn error of (C) amino acid metabolism BCKDHB Maple syrup urine disease, 248611 248600 Metabolic Disorder - RUSP type Ib Inborn error of (C) amino acid metabolism BTD Biotinidase deficiency 609019 253260 Miscellaneous RUSP multisystem (C) diseases BTK Agammaglobulinemia, X- 300300 300755 Primary linked 1 Immunological deficiency CASR Neonatal 601199 601198 Endocrine Disorder hyperparathyroidism / Autosomal dominant hypocalcemia 3 CBS Homocystinuria, B6- 613381 236200 Metabolic Disorder - RUSP responsive and Inborn error of (C) nonresponsive types amino acid metabolism CD247 Immunodeficiency 25 186780 610163 Primary Immunological deficiency CD320 Methylmalonic aciduria, 606475 613646 Metabolic Disorder - transient, due to Inborn error of transcobalamin receptor organic acid defect metabolism CD3D Immunodeficiency 19 186790 615617 Primary Immunological deficiency CD3E Immunodeficiency 18 186830 615615 Primary Immunological deficiency CFTR Cystic fibrosis 602421 219700 Miscellaneous RUSP multisystem (C) diseases COL4A3 Alport syndrome COL4A3- 120070 104200 related COL4A4 Alport syndrome, autosomal 120131 203780 recessive COL4A5 Alport syndrome 303630 301050 CPS1 Carbamoylphosphate 608307 237300 Metabolic Disorder - synthetase I deficiency Inborn error of amino acid metabolism CPT1A Carnitine 600528 255120 Metabolic Disorder - RUSP palmitoyltransferase type I Inborn error of fatty (S) deficiency acid metabolism CPT2 Carnitine 600650 255110 Metabolic Disorder - RUSP palmitoyltransferase type II Inborn error of fatty (S) deficiency acid metabolism CTH Cystathioninuria 607657 219500 Metabolic Disorder - Inborn error of amino acid metabolism 4 CTNS Cystinosis 606272 219800 Lysosomal Storage Disorders (LSD) CYBA Chronic granulomatous 608508 233690 disease, autosomal, due to deficiency of CYBA CYBB Chronic granulomatous 300481 306400 disease CYBB-related CYP11B1 Congenital adrenal 610613 202010 Endocrine Disorder hyperplasia due to 11-beta- hydroxylase deficiency CYP11B2 Corticosterone 124080 610600 methyloxidase deficiency CYP21A2 Adrenal hyperplasia, 613815 201910 Endocrine Disorder RUSP congenital, due to 21- (C) hydroxylase deficiency CYP27A1 Cerebrotendinous 606530 213700 Other Disorders xanthomatosis DBT Maple syrup urine disease, 248610 248600 Metabolic Disorder - RUSP type II Inborn error of (C) amino acid metabolism DCLRE1C Omenn syndrome / Severe 605988 603554 Primary combined Immunological immunodeficiency, deficiency Athabaskan-type DECR1 2,4-dienoyl-CoA reductase 222745 Metabolic Disorder - deficiency Inborn error of fatty acid metabolism DLD Dihydrolipoamide 238331 246900 Metabolic Disorder - dehydrogenase deficiency Organic Acidemias DNAJC19 Hyperphenylalaninemia, 606060 617384 Metabolic Disorder - RUSP mild, non-BH4-deficient Inborn error of (S) amino acid metabolism DUOX2 Thyroid dyshormonogenesis 606759 607200 Endocrine Disorder 6 5 DUOXA2 Thyroid dyshormonogenesis 612772 274900 Endocrine Disorder 5 EPB42 Spherocytosis, type 6 177070 612690 ETFA Glutaric acidemia IIA 608053 231680 Metabolic Disorder - RUSP Inborn error of fatty (S) acid metabolism ETFB Glutaric acidemia IIB 130410 231680 Metabolic Disorder - RUSP Inborn error of fatty (S) acid metabolism ETFDH Glutaric acidemia IIC 231675 231680 Metabolic Disorder - RUSP Inborn error of fatty (S) acid metabolism ETHE1 Ethylmalonic 608451 602473 Metabolic Disorder - encephalopathy Organic Acidemias F9 Factor IX deficiency 300746 300807 FAH Tyrosinemia, type I 613871 276700 Metabolic Disorder - RUSP Inborn error of (C) amino acid metabolism FBN1 Marfan syndrome and 134797 154700 other FBN1-related disorders FBP1 Fructose-1,6- 611570 229700 Metabolic Disorder - bisphosphatase deficiency Organic Acidemias FOLR1 Neurodegeneration due to 136430 613068 Other Disorders cerebral folate transport deficiency FTCD Glutamate 606806 229100 Metabolic Disorder - formiminotransferase Organic Acidemias deficiency G6PC Glycogen storage disease, 613742 232200 Metabolic Disorder - type Ia Inborn error of organic acid metabolism G6PD Hemolytic anemia, G6PD 305900 300908 Miscellaneous deficient (favism) multisystem diseases 6 GAA Glycogen storage disease II - 606800 232300 Lysosomal Storage RUSP Pompe disease Disorders (LSD) (C) GALC Krabbe disease 606890 245200 Lysosomal Storage Disorders (LSD) GALE Galactose epimerase 606953 230350 Miscellaneous RUSP deficiency multisystem (S) diseases GALK1 Galactokinase deficiency 604313 230200 Miscellaneous RUSP with cataracts multisystem (S) diseases GALNS Mucopolysaccharidosis IVA 612222 253000 Lysosomal Storage Disorders (LSD) GALT Galactosemia 606999 230400 Miscellaneous RUSP multisystem (C) diseases GAMT Cerebral creatine deficiency 601240 612736 syndrome 2 GATM Cerebral creatine deficiency 602360 612718 syndrome GBA Gaucher disease, type I 606463 230800 Lysosomal Storage Disorders (LSD) GCDH Glutaricaciduria, type I 608801 231670 Metabolic Disorder - RUSP Inborn error of (C) organic acid metabolism GCH1 Hyperphenylalaninemia, 600225 233910 Metabolic Disorder - RUSP BH4-deficient, B Inborn error of (S) amino acid metabolism GJB2 Deafness, autosomal 121011 220290 Deafness RUSP recessive 1A (C) GJB3 Deafness, digenic, 603324 220290 Deafness RUSP GJB2/GJB3 (C) GJB6 Deafness, digenic 604418 220290 Deafness RUSP GJB2/GJB6 (C) GLA Fabry disease 300644 301500 Lysosomal Storage Disorders (LSD) GLIS3 Diabetes mellitus, neonatal, 610192 610199 Endocrine Disorder with congenital hypothyroidism 7 GLUD1 congenital hyperinsulinic 138130 606762 Endocrine Disorders hyperammonemia (HI/HA) syndrome GNAS Pseudohypoparathyroidism 139320 103580 Endocrine Disorders Ia GNAS Pseudohypoparathyroidism 139320 603233 Endocrine Disorders Ib GNAS Pseudohypoparathyroidism 139320 612462 Endocrine Disorders Ic GNAS Pseudopseudohypoparathyr 139320 612463 Endocrine Disorders oidism GNMT Glycine N- 606628 606664 Metabolic Disorder - methyltransferase Inborn error of deficiency amino acid metabolism GRHPR Hyperoxaluria, primary, 604296 260000 Metabolic Disorder - type II Inborn error of amino acid metabolism GSS Glutathione synthetase 601002 266130 Metabolic Disorder - deficiency - 5-oxoprolinuria Inborn error of amino acid
Recommended publications
  • NDUFAF1 Antibody

    NDUFAF1 Antibody

    Efficient Professional Protein and Antibody Platforms NDUFAF1 Antibody Basic information: Catalog No.: UPA63763 Source: Rabbit Size: 50ul/100ul Clonality: monoclonal Concentration: 1mg/ml Isotype: Rabbit IgG Purification: Protein A purified. Useful Information: WB:1:1000 ICC:1:50-1:200 Applications: IHC:1:50-1:200 FC:1:50-1:100 Reactivity: Human Specificity: This antibody recognizes NDUFAF1 protein. Immunogen: Synthetic peptide within C terminal human NDUFAF1. This gene encodes a complex I assembly factor protein. Complex I (NADH-ubiquinone oxidoreductase) catalyzes the transfer of electrons from NADH to ubiquinone (coenzyme Q) in the first step of the mitochondrial respiratory chain, resulting in the translocation of protons across the inner mitochondrial membrane. The encoded protein is required for assembly of complex I, and mutations in this gene are a cause of mitochondrial complex I deficiency. Alternatively spliced transcript variants have been observed for Description: this gene, and a pseudogene of this gene is located on the long arm of chromosome 19. Part of the mitochondrial complex I assembly (MCIA) com- plex. The complex comprises at least TMEM126B, NDUFAF1, ECSIT, and ACAD9. Interacts with ECSIT. Interacts with ACAD9. At early stages of com- plex I assembly, it is found in intermediate subcomplexes that contain dif- ferent subunits including NDUFB6, NDUFA6, NDUFA9, NDUFS3, NDUFS7, ND1, ND2 and ND3 Uniprot: Q9Y375 Human BiowMW: 38 kDa Buffer: 1*TBS (pH7.4), 1%BSA, 50%Glycerol. Preservative: 0.05% Sodium Azide. Storage: Store at 4°C short term and -20°C long term. Avoid freeze-thaw cycles. Note: For research use only, not for use in diagnostic procedure.
  • Molecular Mechanism of ACAD9 in Mitochondrial Respiratory Complex 1 Assembly

    Molecular Mechanism of ACAD9 in Mitochondrial Respiratory Complex 1 Assembly

    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.07.425795; this version posted January 9, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Molecular mechanism of ACAD9 in mitochondrial respiratory complex 1 assembly Chuanwu Xia1, Baoying Lou1, Zhuji Fu1, Al-Walid Mohsen2, Jerry Vockley2, and Jung-Ja P. Kim1 1Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, USA 2Department of Pediatrics, University of Pittsburgh School of Medicine, University of Pittsburgh, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA 15224, USA Abstract ACAD9 belongs to the acyl-CoA dehydrogenase family, which catalyzes the α-β dehydrogenation of fatty acyl-CoA thioesters. Thus, it is involved in fatty acid β-oxidation (FAO). However, it is now known that the primary function of ACAD9 is as an essential chaperone for mitochondrial respiratory complex 1 assembly. ACAD9 interacts with ECSIT and NDUFAF1, forming the mitochondrial complex 1 assembly (MCIA) complex. Although the role of MCIA in the complex 1 assembly pathway is well studied, little is known about the molecular mechanism of the interactions among these three assembly factors. Our current studies reveal that when ECSIT interacts with ACAD9, the flavoenzyme loses the FAD cofactor and consequently loses its FAO activity, demonstrating that the two roles of ACAD9 are not compatible. ACAD9 binds to the carboxy-terminal half (C-ECSIT), and NDUFAF1 binds to the amino-terminal half of ECSIT. Although the binary complex of ACAD9 with ECSIT or with C-ECSIT is unstable and aggregates easily, the ternary complex of ACAD9-ECSIT-NDUFAF1 (i.e., the MCIA complex) is soluble and extremely stable.
  • CBS, MET Act Sheet

    CBS, MET Act Sheet

    Newborn Screening ACT Sheet Increased Methionine Homocystinuria (CBS Deficiency) / Hypermethioninemia (MET) Differential Diagnosis: Classical homocystinuria (cystathionine β-synthase (CBS) deficiency); hypermethioninemia (MET) due to methionine adenosyltransferase I/III MAT I/III deficiency; glycine n-methyltransferase GNMT deficiency; adenosylhomocysteine hydrolase deficiency; liver disease; hyperalimentation. Condition Description: Methionine from ingested protein is normally converted to homocysteine. In classical homocystinuria due to CBS deficiency, homocysteine cannot be converted to cystathionine. As a result, the concentration of homocysteine and its precursor, methionine, will become elevated. In MAT I/III deficiency and the other hypermethioninemias, methionine is increased in the absence of, or only with, a slightly increased level of homocysteine. You Should Take the Following IMMEDIATE Actions • Contact family to inform them of the newborn screening result and ascertain clinical status. • Consult with pediatric metabolic specialist. (See attached list.) • Evaluate the newborn with attention to liver disease and refer as appropriate. • Initiate confirmatory/diagnostic tests in consultation with metabolic specialist. • Initial testing: Plasma quantitative amino acids and plasma total homocysteine. • Repeat newborn screen if second screen has not been done. • Educate family about homocystinuria and its management as appropriate. • Report findings to newborn screening program. Diagnostic Evaluation: Plasma quantitative amino
  • Incidence of Inborn Errors of Metabolism by Expanded Newborn

    Incidence of Inborn Errors of Metabolism by Expanded Newborn

    Original Article Journal of Inborn Errors of Metabolism & Screening 2016, Volume 4: 1–8 Incidence of Inborn Errors of Metabolism ª The Author(s) 2016 DOI: 10.1177/2326409816669027 by Expanded Newborn Screening iem.sagepub.com in a Mexican Hospital Consuelo Cantu´-Reyna, MD1,2, Luis Manuel Zepeda, MD1,2, Rene´ Montemayor, MD3, Santiago Benavides, MD3, Hector´ Javier Gonza´lez, MD3, Mercedes Va´zquez-Cantu´,BS1,4, and Hector´ Cruz-Camino, BS1,5 Abstract Newborn screening for the detection of inborn errors of metabolism (IEM), endocrinopathies, hemoglobinopathies, and other disorders is a public health initiative aimed at identifying specific diseases in a timely manner. Mexico initiated newborn screening in 1973, but the national incidence of this group of diseases is unknown or uncertain due to the lack of large sample sizes of expanded newborn screening (ENS) programs and lack of related publications. The incidence of a specific group of IEM, endocrinopathies, hemoglobinopathies, and other disorders in newborns was obtained from a Mexican hospital. These newborns were part of a comprehensive ENS program at Ginequito (a private hospital in Mexico), from January 2012 to August 2014. The retrospective study included the examination of 10 000 newborns’ results obtained from the ENS program (comprising the possible detection of more than 50 screened disorders). The findings were the following: 34 newborns were confirmed with an IEM, endocrinopathies, hemoglobinopathies, or other disorders and 68 were identified as carriers. Consequently, the estimated global incidence for those disorders was 3.4 in 1000 newborns; and the carrier prevalence was 6.8 in 1000. Moreover, a 0.04% false-positive rate was unveiled as soon as diagnostic testing revealed negative results.
  • Birth Prevalence of Disorders Detectable Through Newborn Screening by Race/Ethnicity

    Birth Prevalence of Disorders Detectable Through Newborn Screening by Race/Ethnicity

    ©American College of Medical Genetics and Genomics ORIGINAL RESEARCH ARTICLE Birth prevalence of disorders detectable through newborn screening by race/ethnicity Lisa Feuchtbaum, DrPH, MPH1, Jennifer Carter, MPH2, Sunaina Dowray, MPH2, Robert J. Currier, PhD1 and Fred Lorey, PhD1 Purpose: The purpose of this study was to describe the birth prev- Conclusion: The California newborn screening data offer a alence of genetic disorders among different racial/ethnic groups unique opportunity to explore the birth prevalence of many through population-based newborn screening data. genetic dis orders across a wide spectrum of racial/ethnicity classifications. The data demonstrate that racial/ethnic subgroups Methods: Between 7 July 2005 and 6 July 2010 newborns in Cali- of the California newborn population have very different patterns fornia were screened for selected metabolic, endocrine, hemoglobin, of heritable disease expression. Determining the birth prevalence and cystic fibrosis disorders using a blood sample collected via heel of these disorders in California is a first step to understanding stick. The race and ethnicity of each newborn was self-reported by the short- and long-term medical and treatment needs faced by the mother at the time of specimen collection. affected communities, especially those groups that are impacted by Results: Of 2,282,138 newborns screened, the overall disorder detec- more severe disorders. tion rate was 1 in 500 births. The disorder with the highest prevalence Genet Med 2012:14(11):937–945 among all groups was primary congenital hypothyroidism (1 in 1,706 births). Birth prevalence for specific disorders varied widely among Key Words: birth prevalence; disorders; newborn screening; race different racial/ethnic groups.
  • Inherited Metabolic Disease

    Inherited Metabolic Disease

    Inherited metabolic disease Dr Neil W Hopper SRH Areas for discussion • Introduction to IEMs • Presentation • Initial treatment and investigation of IEMs • Hypoglycaemia • Hyperammonaemia • Other presentations • Management of intercurrent illness • Chronic management Inherited Metabolic Diseases • Result from a block to an essential pathway in the body's metabolism. • Huge number of conditions • All rare – very rare (except for one – 1:500) • Presentation can be non-specific so index of suspicion important • Mostly AR inheritance – ask about consanguinity Incidence (W. Midlands) • Amino acid disorders (excluding phenylketonuria) — 18.7 per 100,000 • Phenylketonuria — 8.1 per 100,000 • Organic acidemias — 12.6 per 100,000 • Urea cycle diseases — 4.5 per 100,000 • Glycogen storage diseases — 6.8 per 100,000 • Lysosomal storage diseases — 19.3 per 100,000 • Peroxisomal disorders — 7.4 per 100,000 • Mitochondrial diseases — 20.3 per 100,000 Pathophysiological classification • Disorders that result in toxic accumulation – Disorders of protein metabolism (eg, amino acidopathies, organic acidopathies, urea cycle defects) – Disorders of carbohydrate intolerance – Lysosomal storage disorders • Disorders of energy production, utilization – Fatty acid oxidation defects – Disorders of carbohydrate utilization, production (ie, glycogen storage disorders, disorders of gluconeogenesis and glycogenolysis) – Mitochondrial disorders – Peroxisomal disorders IMD presentations • ? IMD presentations • Screening – MCAD, PKU • Progressive unexplained neonatal
  • Inborn Errors of Metabolism Test Requisition

    Inborn Errors of Metabolism Test Requisition

    LABORATORY OF GENETICS AND GENOMICS Mailing Address: For local courier service and/or inquiries, please contact 513-636-4474 • Fax: 513-636-4373 3333 Burnet Avenue, Room R1042 www.cincinnatichildrens.org/moleculargenetics • Email: [email protected] Cincinnati, OH 45229 INBORN ERRORS OF METABOLISM TEST REQUISITION All Information Must Be Completed Before Sample Can Be Processed PATIENT INFORMATION ETHNIC/RACIAL BACKGROUND (Choose All) Patient Name: ___________________ , ___________________ , ________ European American (White) African-American (Black) Last First MI Native American or Alaskan Asian-American Address: ____________________________________________________ Pacific Islander Ashkenazi Jewish ancestry ____________________________________________________ Latino-Hispanic _____________________________________________ Home Phone: ________________________________________________ (specify country/region of origin) MR# __________________ Date of Birth ________ / ________ / _______ Other ____________________________________________________ (specify country/region of origin) Gender: Male Female BILLING INFORMATION (Choose ONE method of payment) o REFERRING INSTITUTION o COMMERCIAL INSURANCE* Insurance can only be billed if requested at the time of service. Institution: ____________________________________________________ Policy Holder Name: _____________________________________________ Address: _____________________________________________________ Gender: ________________ Date of Birth ________ / ________ / _______
  • An Essential Role for ECSIT in Mitochondrial Complex I Assembly and Mitophagy in Macrophages

    An Essential Role for ECSIT in Mitochondrial Complex I Assembly and Mitophagy in Macrophages

    Article An Essential Role for ECSIT in Mitochondrial Complex I Assembly and Mitophagy in Macrophages Graphical Abstract Authors Fla´ via R.G. Carneiro, Alice Lepelley, John J. Seeley, Matthew S. Hayden, Sankar Ghosh Correspondence [email protected] In Brief Macrophages rely on fine-tuning their metabolism to fulfill their anti-bacterial functions. Carneiro et al. show that the complex I assembly factor ECSIT is an essential regulator of the balance between mitochondrial respiration and glycolysis and the maintenance of a healthy mitochondrial pool through mitophagy. Highlights d Loss of ECSIT in macrophages leads to a striking glycolytic shift d ECSIT is essential for complex I assembly and stability in macrophages d Role of ECSIT in mROS production and removal of damaged mitochondria by mitophagy Carneiro et al., 2018, Cell Reports 22, 2654–2666 March 6, 2018 ª 2018 The Author(s). https://doi.org/10.1016/j.celrep.2018.02.051 Cell Reports Article An Essential Role for ECSIT in Mitochondrial Complex I Assembly and Mitophagy in Macrophages Fla´ via R.G. Carneiro,1,3,4 Alice Lepelley,1,4 John J. Seeley,1 Matthew S. Hayden,1,2 and Sankar Ghosh1,5,* 1Department of Microbiology and Immunology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA 2Section of Dermatology, Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA 3FIOCRUZ, Center for Technological Development in Health (CDTS), Rio de Janeiro, Brazil 4These authors contributed equally 5Lead Contact *Correspondence: [email protected] https://doi.org/10.1016/j.celrep.2018.02.051 SUMMARY 2015). There, ECSIT-dependent mROS production promotes activation of the phagosomal nicotinamide adenine dinucleotide ECSIT is a mitochondrial complex I (CI)-associated phosphate (NADPH) oxidase system and ROS-dependent protein that has been shown to regulate the pro- killing of engulfed microbes (West et al., 2011).
  • Genetic and Genomic Analysis of Hyperlipidemia, Obesity and Diabetes Using (C57BL/6J × TALLYHO/Jngj) F2 Mice

    Genetic and Genomic Analysis of Hyperlipidemia, Obesity and Diabetes Using (C57BL/6J × TALLYHO/Jngj) F2 Mice

    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Nutrition Publications and Other Works Nutrition 12-19-2010 Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice Taryn P. Stewart Marshall University Hyoung Y. Kim University of Tennessee - Knoxville, [email protected] Arnold M. Saxton University of Tennessee - Knoxville, [email protected] Jung H. Kim Marshall University Follow this and additional works at: https://trace.tennessee.edu/utk_nutrpubs Part of the Animal Sciences Commons, and the Nutrition Commons Recommended Citation BMC Genomics 2010, 11:713 doi:10.1186/1471-2164-11-713 This Article is brought to you for free and open access by the Nutrition at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Nutrition Publications and Other Works by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. Stewart et al. BMC Genomics 2010, 11:713 http://www.biomedcentral.com/1471-2164/11/713 RESEARCH ARTICLE Open Access Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice Taryn P Stewart1, Hyoung Yon Kim2, Arnold M Saxton3, Jung Han Kim1* Abstract Background: Type 2 diabetes (T2D) is the most common form of diabetes in humans and is closely associated with dyslipidemia and obesity that magnifies the mortality and morbidity related to T2D. The genetic contribution to human T2D and related metabolic disorders is evident, and mostly follows polygenic inheritance. The TALLYHO/ JngJ (TH) mice are a polygenic model for T2D characterized by obesity, hyperinsulinemia, impaired glucose uptake and tolerance, hyperlipidemia, and hyperglycemia.
  • Amyloid Like Aggregates Formed by the Self-Assembly of Proline And

    Amyloid Like Aggregates Formed by the Self-Assembly of Proline And

    Please do not adjust margins Journal Name ARTICLE Amyloid like aggregates formed by the self-assembly of proline and Hydroxyproline Bharti Koshtia, Ramesh Singh Chilwalb, Vivekshinh Kshtriyaa, Shanka Walia c, Dhiraj Bhatiac, K.B. Joshib* and Nidhi Goura* a Department of Chemistry, Indrashil University, Mehsana, Gujarat, India b Department of Chemistry, Dr. Hari Singh Gour, Sagar University, Madhya Pradesh, India c Biological Engineering Discipline, Indian Institute of Technology Gandhinagar, Gujarat, India Abstract: Single amino acid based self-assembled structures have gained a lot of interest recently owing to their pathological significance in metabolite disorders. There is plethora of significant research work which illustrate amyloid like characteristics of assemblies formed by aggregation of single amino acids like Phenylalanine, Tyrosine, Tryptophan, Cysteine and Methionine and its implications in pathophysiology of single amino acid metabolic disorders like phenylketonuria, tyrosinemia, hypertryptophanemia, cystinuria and hypermethioninemia respectively. Hence, studying aggregation behaviour of single amino acids is very crucial to assess the underlying molecular mechanism behind metabolic disorders. In this manuscript we report for the very first time the aggregation properties of non-aromatic single amino acids Hydroxy-proline and Proline. The morphologies of these were studied extensively by Optical microscopy (OM), ThT binding fluorescence microscopy, Scanning Electron Microscopy (SEM) and Atomic force microscopy (AFM). It can be assessed that these amino acids form globular structures at lower concentrations and gradually changes to tape like structures on increasing the This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 1 Please do not adjust margins Please do not adjust margins Journal Name ARTICLE concentration as assessed by AFM.
  • CDH12 Cadherin 12, Type 2 N-Cadherin 2 RPL5 Ribosomal

    CDH12 Cadherin 12, Type 2 N-Cadherin 2 RPL5 Ribosomal

    5 6 6 5 . 4 2 1 1 1 2 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 A A A A A A A A A A A A A A A A A A A A C C C C C C C C C C C C C C C C C C C C R R R R R R R R R R R R R R R R R R R R B , B B B B B B B B B B B B B B B B B B B , 9 , , , , 4 , , 3 0 , , , , , , , , 6 2 , , 5 , 0 8 6 4 , 7 5 7 0 2 8 9 1 3 3 3 1 1 7 5 0 4 1 4 0 7 1 0 2 0 6 7 8 0 2 5 7 8 0 3 8 5 4 9 0 1 0 8 8 3 5 6 7 4 7 9 5 2 1 1 8 2 2 1 7 9 6 2 1 7 1 1 0 4 5 3 5 8 9 1 0 0 4 2 5 0 8 1 4 1 6 9 0 0 6 3 6 9 1 0 9 0 3 8 1 3 5 6 3 6 0 4 2 6 1 0 1 2 1 9 9 7 9 5 7 1 5 8 9 8 8 2 1 9 9 1 1 1 9 6 9 8 9 7 8 4 5 8 8 6 4 8 1 1 2 8 6 2 7 9 8 3 5 4 3 2 1 7 9 5 3 1 3 2 1 2 9 5 1 1 1 1 1 1 5 9 5 3 2 6 3 4 1 3 1 1 4 1 4 1 7 1 3 4 3 2 7 6 4 2 7 2 1 2 1 5 1 6 3 5 6 1 3 6 4 7 1 6 5 1 1 4 1 6 1 7 6 4 7 e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m
  • Dietary Amylose:Amylopectin Ratio Influences the Expression of Amino Acid Transporters and Enzyme Activities for Amino Acid Meta

    Dietary Amylose:Amylopectin Ratio Influences the Expression of Amino Acid Transporters and Enzyme Activities for Amino Acid Meta

    Downloaded from British Journal of Nutrition, page 1 of 11 doi:10.1017/S0007114521002087 https://www.cambridge.org/core © The Author(s), 2021. Published by Cambridge University Press on behalf of The Nutrition Society. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. Dietary amylose:amylopectin ratio influences the expression of amino acid transporters and enzyme activities for amino acid metabolism in the gastrointestinal tract of goats . IP address: 170.106.202.226 Xiaokang Lv1,2, Chuanshe Zhou1,2*, Tao Ran3, Jinzhen Jiao1, Yong Liu1, Zhiliang Tan1, Shaoxun Tang1, Jinhe Kang1, Jingjing Xie1, Liang Chen1, Ao Ren4, Qixiang Xv1,2 and Zhiwei Kong1 1CAS Key Laboratory of Agro-ecological Processes in Subtropical Region, National Engineering Laboratory for Pollution Control and Waste Utilization in Livestock and Poultry Production, Hunan Provincial Key Laboratory of Animal Nutrition & Physiology , on and Metabolism, Institute of Subtropical Agriculture, the Chinese Academy of Sciences, Changsha 410125, People’s Republic of 28 Sep 2021 at 13:00:40 China 2University of Chinese Academy of Sciences, Beijing 100049, People’s Republic of China 3College of Pastoral Agriculture Science and Technology, Lanzhou University, Lanzhou 730020, People’s Republic of China 4Department of Animal Science and Technology, University of Hunan Agricultural University, Changsha 410128, People’s Republic of China , subject to the Cambridge Core terms of use, available at (Submitted 12 March 2021 – Final revision received 25 May 2021 – Accepted 8 June 2021) Abstract This study was designed to investigate the effects of dietary starch structure on muscle protein synthesis and gastrointestinal amino acid (AA) transport and metabolism of goats.